Literature DB >> 22279622

Comparison of the 2-step tuberculin skin test and the quantiFERON-TB Gold In-Tube Test for the screening of tuberculosis infection before liver transplantation.

Susana Casas1, Laura Muñoz, Raquel Moure, Jose Castellote, Maria R Guerra, Lucia Gonzalez, Ana Andreu, Antoni G Rafecas, Fernando Alcaide, Miguel Santin.   

Abstract

The ability of interferon-gamma release assays (IGRAs) to detect latent tuberculosis (TB) infection before liver transplantation (LT)is not well established. The aims of this study were (1) to compare the ability of the tuberculin skin test (TST) and the QuantiFERON-TB Gold In-Tube (QFT-IT) test (a whole-blood IGRA) to diagnose latent TB infections in patients awaiting LT and (2) to correlate the results with the severity of liver disease. We conducted a prospective, cross-sectional study of patients who were evaluated for LT between July 2008 and July 2010. The 95 patients who were included underwent the 2-step TST and the QFT-IT test. The mean Model for End-Stage Liver Disease (MELD) score was 13.8. Forty-four patients (46.3%) had positive TST results, 42 (44.2%) had positive QFT-IT results, and 2 (2.1%) had indeterminate QFT-IT results. Simultaneous TST and QFT-IT testing yielded a positivity rate of 55.8% [95% confidence interval (CI) = 45.3-65.9] with either test, and the 2-step TST yielded a positivity rate of 46.3% (95% CI = 36.1-56.8); the difference was 9.5% (P = 0.004). In an adjusted analysis, the rates for positive TST results were lower in patients with MELD scores > or = 18 [odds ratio (OR) = 0.2, 95% CI = 0.04-0.7], lower in Child-Pugh-Turcotte (CPT) class C patients versus CPT class A patients (OR = 0.1, 95% CI = 0.02-0.6), and higher in males (OR = 6.4, 95% CI = 1.9-22.0). In contrast, only being male (OR = 3.5, 95% CI = 1.1-11.0) was associated with positive QFT-IT results; no association was found with the MELD score (OR = 0.8, 95% CI = 0.2-2.8) or the CPT class (OR = 0.3; 0.05-1.4). In conclusion, the QFT-IT test is better than the TST for detecting latent TB infection in patients with more advanced liver disease. Our results support the regular use of the QFT-IT test for screening patients with end-stage liver disease for latent TB infection before LT.

Entities:  

Mesh:

Year:  2011        PMID: 22279622     DOI: 10.1002/lt.22375

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  7 in total

1.  Tuberculosis in transplantation: diagnosis, prevention, and treatment.

Authors:  Sarah Kirsch; Martina Sester
Journal:  Curr Infect Dis Rep       Date:  2012-12       Impact factor: 3.725

2.  Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON® -TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant.

Authors:  Jonathan Hand; Keith Sigel; Shirish Huprikar; Camille Hamula; Meena Rana
Journal:  Transpl Infect Dis       Date:  2018-02-19       Impact factor: 2.228

3.  Immunodiagnostic Tests' Predictive Values for Progression to Tuberculosis in Transplant Recipients: A Prospective Cohort Study.

Authors:  Laura Muñoz; Aina Gomila; Susana Casas; José Castellote; Montserrat Arnan; Antoni Rafecas; Miguel Santin
Journal:  Transplant Direct       Date:  2015-04-01

4.  Interferon-gamma release assay for the diagnosis of latent tuberculosis infection: A latent-class analysis.

Authors:  Tan N Doan; Damon P Eisen; Morgan T Rose; Andrew Slack; Grace Stearnes; Emma S McBryde
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

5.  Latent tuberculosis: Risk factors, screening and treatment in liver transplantation recipients from an endemic area.

Authors:  Isabela Dias Lauar; Luciana Costa Faria; Roberta Maia de Castro Romanelli; Wanessa Trindade Clemente
Journal:  World J Transplant       Date:  2021-12-18

6.  Agreement between the results of tuberculin skin test and Interferon-Gamma Release Assays in renal transplant candidates.

Authors:  Shiva Samavat; Sam Alahyari; Ali Sangian; Malihe Nasiri; Mohsen Nafar; Ahmad Firoozan; Fariba Samadian; Nooshin Dalili; Fatemeh Poorrezagholi
Journal:  J Res Med Sci       Date:  2021-10-18       Impact factor: 1.852

Review 7.  Diagnostic Value of Interferon-Gamma Release Assays for Tuberculosis in the Immunocompromised Population.

Authors:  Ying Yang; Hong-Jiao Wang; Wei-Lin Hu; Guan-Nan Bai; Chun-Zhen Hua
Journal:  Diagnostics (Basel)       Date:  2022-02-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.